RenovoRx Inc
RNXT
View Detailed Chart
1.330USD
+0.070+5.56%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
48.74MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.56%
5 Days
+3.91%
1 Month
+44.35%
6 Months
+36.55%
Year to Date
+3.10%
1 Year
+35.16%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.625
Target Price
+346.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.00K.
Undervalued
The company’s latest PE is -3.55, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.72M shares, increasing 30.98% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.66M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.57.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Ticker SymbolRNXT
CompanyRenovoRx Inc
CEOMr. Shaun R. Bagai
Websitehttps://renovorx.com/
Related Instruments
+1.09%
-0.27%
-0.53%
-0.28%
-0.71%
+0.10%
-0.69%
-10.99%
-0.69%
-0.80%
-0.12%
-0.05%
-0.49%
+1.41%
-0.87%
-2.83%
-0.83%
-0.89%
-1.01%
+0.33%
